Medocaryl ceftobiprole is a water-soluble prodrug that exerts bactericidal activity on a relatively large number of gram-positive microbes, among which are resistant to methicillin, staphylococci, penicillin-resistant pneumococci, and in addition entericococci-sensitive fecal ones. In addition, there is activity against a variety of gram-negative microorganisms, among which are strains of enterobacteria and Pseudomonas aeruginosa.
The active component is firmly synthesized with a number of important gram-negative and gram-positive microbes as well as PBP. Ceftobiprol is synthesized with PBP2a by staphylococci (among them are methicillin-resistant Staphylococcus aureus), which is why it actively acts against methicillin-resistant staphylococci.
There is evidence that ceftobiprole has activity against a variety of isolates of the following microbes, both in hospital infections and in vitro.
Aerobic bacteria (Gram-positive): Enterococcus fecal (exclusively isolates with sensitivity / resistance to vancomycin), Staphylococcus aureus (exclusively isolates with resistance / sensitivity to methicillin), Staphylococcus epidermis, Streptococcus agalactia, and in addition streptococcus pyogenic. Also coagulase-negative staphylococci (isolates that are resistant / sensitive to methicillin, amongst which are staphylococcus hemolytic, Staphylococcus hominis, staphylococcus saprophytic, and Staphylococcus lugdunensis), pneumococci (isolates that are resistant / moderately resistant / sensitive to penicillin) and streptococci from the viridans category.
Aerobic microorganisms (Gram-negative): Enterobacter cloaca, E. Coli, Klebsiella pneumonia, Proteus mirabilis and Pseudomonas aeruginosa. In addition, bacteria of the genus tsitrobacter (among them also Citrobacter frowni and Citrobacter koseri), as well as Enterobacter aerogenes, klebsiella oxytoca, moraxella cataralis and morgana bacterium. Along with this, microbes are from the genus Neisseria, Providence and Sercesia Marces.